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Background—Heart failure with preserved left ventricular (LV) ejection fraction (EF) is increasingly recognized and
usually referred to as diastolic heart failure (DHF). Its pathogenetic mechanism remains unclear, partly because of a lack
of myocardial biopsy material. Endomyocardial biopsy samples obtained from DHF patients were therefore analyzed for
collagen volume fraction (CVF) and sarcomeric protein composition and compared with control samples. Single
cardiomyocytes were isolated from these biopsy samples to assess cellular contractile performance.
Methods and Results—DHF patients (n12) had an LVEF of 7111%, an LV end-diastolic pressure (LVEDP) of
284 mm Hg, and no significant coronary artery stenoses. DHF patients had higher CVFs (7.54.0%, P0.05) than
did controls (n8, 3.82.0%), and no conspicuous changes in sarcomeric protein composition were detected.
Cardiomyocytes, mechanically isolated and treated with Triton X-100 to remove all membranes, were stretched to a
sarcomere length of 2.2 m and activated with solutions containing varying [Ca2]. Compared with cardiomyocytes of
controls, cardiomyocytes of DHF patients developed a similar total isometric force at maximal [Ca2], but their resting
tension (Fpassive) in the absence of Ca2 was almost twice as high (6.63.0 versus 3.51.7 kN/m2, P0.001). Fpassive and
CVF combined yielded stronger correlations with LVEDP than did either alone. Administration of protein kinase A
(PKA) to DHF cardiomyocytes lowered Fpassive to control values.
Conclusions—DHF patients had stiffer cardiomyocytes, as evident from a higher Fpassive at the same sarcomere length.
Together with CVF, Fpassive determined in vivo diastolic LV dysfunction. Correction of this high Fpassive by PKA suggests
that reduced phosphorylation of sarcomeric proteins is involved in DHF. (Circulation. 2005;111:774-781.)
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Heart failure with preserved left ventricular (LV) ejectionfraction (EF) is frequently referred to as diastolic heart
failure (DHF) in contrast to systolic heart failure, which is
characterized by HF with reduced LVEF.1–4 DHF is currently
diagnosed in as much as 49% of HF patients.5 Diastolic LV
dysfunction is also increasingly recognized,6 as evident from
a recent population-based survey in which diastolic LV
dysfunction was observed 5 times more often than systolic
LV dysfunction.7
Despite the increased recognition of both DHF and diastol-
ic LV dysfunction, their pathophysiology remains incom-
pletely understood. Whether HF with preserved LVEF results
from diastolic LV dysfunction8 or from subtle systolic LV
dysfunction, unappreciated by a routine LVEF measurement9
and possibly exacerbated by high arterial impedance,10 is still
a matter of debate. Furthermore, explanations proposed for
diastolic LV dysfunction are divergent, ranging from high LV
myocardial stiffness1,8 to pericardial or right ventricular
constraint.11,12 Moreover, the relative importance of myocar-
dial fibrosis and of high cardiomyocyte resting tension for LV
myocardial stiffness remains undefined.13
Failure to resolve these controversies about DHF and
diastolic LV dysfunction could arise from a lack of myocar-
dial biopsy or necropsy material,4,13 which would allow
clinical and hemodynamic features to be matched with
cellular and molecular myocardial properties. We therefore
studied endomyocardial biopsy samples from patients with
DHF in whom sample procurement was requested because of
clinical suspicion of restrictive cardiomyopathy or, in the case
of transplant recipients, because of clinical suspicion of
rejection and in whom subsequent histological examination
revealed no signs of infiltrative myocardial disease or rejec-
tion. Apart from routine histological examination, biopsies
were used for determination of collagen volume fraction
(CVF), sarcomeric protein expression, and isolation of single
cardiomyocytes, whose developed and resting tensions were
measured to detect systolic and/or diastolic dysfunction at the
cellular level.14,15 To evaluate the relative contributions to
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diastolic LV dysfunction of myocardial fibrosis and of
cardiomyocyte resting tension, in vitro data were subse-
quently correlated with in vivo hemodynamic indices of
diastolic LV function.
Methods
Patients
DHF patients were referred for cardiac catheterization and endomyo-
cardial biopsy procurement because of clinical suspicion of restric-
tive cardiomyopathy (n7) or cardiac allograft rejection (n5).
They had all been admitted to hospital because of worsening HF. LV
endomyocardial biopsy samples were obtained from patients sus-
pected of restrictive cardiomyopathy, and RV endomyocardial sam-
ples were obtained from the transplant recipients. Subsequent histo-
logical examination ruled out infiltrative myocardial disease or
rejection in all patients. Coronary angiography showed the absence
of significant coronary artery stenoses or graft vasculopathy. All
patients satisfied the criteria as proposed by the European study
group on DHF,16 ie, signs and symptoms of congestive HF, LVEF
45%, and LVEDP 16 mm Hg. They all had 1 or more predis-
posing risk factors for diastolic LV dysfunction (Table 1).7 LV
muscle mass (11916 g/m2) was larger than normal (9210 g/m2,
P0.05), and 5 patients had significant LV hypertrophy (125
g/m2).
The control group consisted of 6 transplant recipients undergoing
routine annual coronary angiography and biopsy procurement and of
2 patients referred for cardiac catheterization and endomyocardial
biopsy procurement because of clinical suspicion of myocarditis. LV
endomyocardial biopsy samples were obtained from the patients
suspected of myocarditis, and RV endomyocardial samples were
obtained from the transplant recipients. Histological examination
ruled out the presence of myocarditis or rejection in all patients.
They had no signs or symptoms of HF, an LVEF 50%, and an
LVEDP 16 mm Hg.
Mean hemodynamic data of DHF patients and controls are listed
in Table 2; individual hemodynamic data can be found in the Data
Supplement Table. Hemodynamic data were derived from LV
angiograms, 2D echocardiograms, and high-fidelity LV catheter
pressure measurements. The local ethics committee approved the
study protocol. Written, informed consent was obtained from all
patients, and there were no complications related to catheterization
or biopsy sample procurement.
Force Measurements in Isolated Cardiomyocytes
Force measurements were performed in mechanically isolated, single
cardiomyocytes at 15°C as described previously.14 In brief, frozen
biopsy samples (5 mg wet weight) were defrosted in cold relaxing
solution (in mmol/L: free Mg 1, KCl 100, EGTA 2, Mg-ATP 4, and
imidazole 10; pH 7.0), mechanically disrupted, and incubated for 5
minutes in relaxing solution supplemented with 0.2% Triton X-100
to remove all membranes. Thereafter, cells were washed twice in
relaxing solution, and a single cardiomyocyte was attached with
silicone adhesive between a force transducer and a piezoelectric
motor (Figure 1A).
Resting sarcomere length in isolated cardiomyocytes was adjusted
to 2.2 m. Mean length between the attachments, width, and depth
of control cardiomyocytes were 5119, 248, and 185 m,
respectively. Corresponding values of DHF cardiomyocytes were
6925, 2810, and 216 m. The composition of the relaxing and
activating solutions was described previously.17 Their pCa
(10log[Ca2]) ranged from 9.0 (relaxing) to 4.5 (maximal activa-
tion). Maximal activation at pCa 4.5 was used to calculate maximal
calcium-activated isometric force (Fmax). Subsequently, exposure to a
series of solutions with intermediate pCa yielded the force-pCa
relation. All force values were normalized for myocyte cross-
sectional area. A typical contraction-relaxation sequence is shown in
Figure 1B. On transfer of the myocyte from relaxing to activating
solution, isometric force started to develop. Once a steady-state force
level was reached, the cell was shortened within 1 ms to 80% of its
original length (slack test) to determine the baseline of the force
transducer. The distance between the baseline and the steady force
level is the total force (Ftotal). After 20 ms, the cell was restretched
and returned to the relaxing solution, in which a second slack test of
10-second duration was performed to determine resting or passive
force (Fpassive).
After establishing the baseline force-pCa relation, some of the
myocytes were incubated for 40 minutes at 22°C in relaxing solution
containing the catalytic subunit of protein kinase A (PKA, 100
U/mL; Sigma, batch 12K7495) and 6 mmol/L dithiothreitol (MP
Biochemicals). Subsequently, a second force-pCa relation was
determined.
Myocardial Tissue Properties
The extent of interstitial fibrosis was determined on elastica–von
Gieson’s–stained sections of tissue placed in 5% formalin with an
automated image analyzer (Prodit) and was expressed as low (0% to
5%, class I), intermediate (5% to 10%, class II), or high (10% to
15%, class III) CVF.18
Expression of myosin heavy chain, desmin, actin, troponin T
(TnT), tropomyosin, troponin I (TnI), and myosin light-chain 1 and
-2 (MLC-1 and MLC-2) was analyzed by 1D sodium dodecyl
TABLE 1. Clinical Characteristics of DHF Patients
Patient No. Age, y Sex Diagnoses Medications
1 77 F HT ACEI, Amio, CCB, Diu,
Stat
2 66 F HT Amio, ARB, , Dig,
Diu
3 67 M HT, DM, Ob ACEI, Dig, Diu, Nit
4 82 F HT ACEI, , Dig, Diu, Stat
5 71 F HT, DM ACEI, Amio, CCB, Diu
6 71 M HT, DM, Ob ACEI, CCB, Nit, Diu
7 74 F HT ACEI, ARB, CCB, ,
Diu
8 74 M HT, TX ACEI, Amio, Diu, Imm
9 68 M HT, DM, TX ARB, Diu, Fibr, Imm
10 55 M HT, DM, TX Diu, Imm, Stat
11 64 M HT, TX ACEI, Diu, Imm, Stat
12 61 M HT, DM, TX ARB, Diu, Imm, Stat
HT indicates arterial hypertension; DM, diabetes mellitus; Ob, obesity; TX,
transplant recipients; ACEI, angiotensin-converting-enzyme inhibitors; Amio,
amiodarone; CCB, calcium channel blockers; Diu, diuretics; Stat, statins; ARB,
angiotensin II receptor blockers; , -blockers; Dig, digitalis; Nit, nitrates; Imm,
immunosuppressants; and Fibr, fibrates.
TABLE 2. LV Systolic and Diastolic Function of Control and DHF Groups (MeanSD)
HR, bpm LVPSP, mm Hg LVEDP, mm Hg LVEDVI, mL/m2 LVEF, % CI, L/min per m2 , kN/m2 E, kN/m2
Control 8016 13515 134 7823 7112 2.70.6 1.60.3 2.20.7
DHF 8411 18635* 284* 7416 7111 2.80.6 5.11.1* 4.61.2*
HR indicates heart rate; LVPSP, left ventricular peak systolic pressure; LVEDVI, left ventricular end-diastolic volume index; and CI, cardiac index.
*P0.05, DHF vs controls.
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sulfate–polyacrylamide gel electrophoresis as described previous-
ly.15 To detect degradation products of myofilament proteins, West-
ern immunoblot analysis was performed with specific monoclonal
antibodies against desmin (clone DE-U-10, Sigma), TnT (clone 2G3,
Spectral Diagnostics), TnI (clone 8I-7, Spectral Diagnostics), and
MLC-1 and MLC-2 (clones F109.16A12 and F109.3E1, Alexis).
Signals were visualized with a secondary horseradish peroxidase–
labeled goat-anti-mouse antibody and enhanced chemiluminescence
(Amersham Biosciences).
An ELISA was used to determine the phosphorylation status of
TnI with specific monoclonal antibodies against whole TnI (clone
16A11) and dephosphorylated TnI (clone 22B11).19 Biopsy samples
were treated with 10% trichloroacetic acid to preserve the phosphor-
ylation status of proteins.
Data Analysis
Circumferential LV end-diastolic wall stress () was computed by
using a thick-wall ellipsoid model of the LV: PD/2h[1
(h/D)(D2/2L2)], where P is LVEDP, h is echocardiographically
determined LV wall thickness, and D and L are LV short-axis
diameter and long-axis length at the midwall, respectively.20
The radial myocardial stiffness modulus (E) was calculated to
assess myocardial material properties from the formula: ER/
RP/(h/h)P/ln h and assuming the increment in radial
stress (R) to be equal but opposite in sign to the increment in P
at the endocardium and the increment in radial strain (R) to be
equal to the increment in wall thickness (h) relative to the
instantaneous wall thickness. Because h/hln h, E equals the
slope of a P versus ln h plot.18,21 Agreement between E and diastolic
LV stiffness indices derived from multiple beat analyses during caval
occlusion has previously been reported in patients with dilated
cardiomyopathy.22
The Hill constant (nHill), a measure of the steepness of the
sigmoidal force-pCa relation, was derived from a modified Hill
equation fitted to the individual force-pCa data points of each
myocyte: FtotalFmax[Ca2]nHill/(Ca50nHill[Ca2]nHill)Fpassive, where
Ca50 (or pCa50) corresponds to the [Ca2] at which
FtotalFpassiveFmax/2. pCa50 is a measure of Ca2 sensitivity of the
contractile apparatus.
Values are given as meanSD. Statistical significance was set at
P0.05 and was obtained for multiple comparisons between groups
by ANOVA followed by a Bonferroni test and for single compari-
sons by an unpaired Student t test. Monovariate and bivariate linear
regression analyses were performed with SPSS (version 9.0).
Results
Hemodynamic Characteristics of the DHF Patients
The mean hemodynamic data of the DHF group are compared
with that of the control group in Table 2. Heart rate, LVEF,
LV end-diastolic volume index, and cardiac index in the DHF
group were similar to the values measured in the control
group. LV peak systolic pressure, LV end-diastolic volume
index, , and E were significantly higher in the DHF group.
The higher LVEDP and  at comparable LVEDVI implied a
reduced LV diastolic distensibility and the higher E, in-
creased myocardial stiffness.16
Force Measurements in Single Cardiomyocytes
The average force-pCa relations obtained for 6 control and 9
DHF patients are shown in Figure 2A. Ftotal at pCa 4.5 did not
significantly differ between the DHF (20.37.5 kN/m2;
number of myocytes, n23) and the control (24.212.4
kN/m2, n15) groups. However, Fpassive was significantly
higher in the DHF (6.63.0 kN/m2) than in the control
(3.51.7 kN/m2, P0.001) group. A higher Fpassive than in the
control group was observed in both types of DHF patients:
those who were transplant recipients (5.41.1 kN/m2,
P0.05) and those who were not (7.22.9 kN/m2, P0.01).
The Fpassive of the control group was comparable to previously
reported values of cardiomyocytes isolated from nonfailing
Figure 1. A, Single cardiomyocyte, iso-
lated from endomyocardial biopsy sam-
ple from DHF patient, mounted between
force transducer and piezoelectric motor.
B, Contraction-relaxation sequence rec-
orded in single cardiomyocyte before
and after PKA treatment during maximal
(pCa 4.5) and submaximal (pCa 5.8) acti-
vation. *Slack test (see text).
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donor hearts.14,15 No significant differences were found be-
tween the 2 groups in terms of Ca2 sensitivity of the
contractile apparatus (pCa50) and the steepness of the force-
pCa curves (ie, nHill; Table 3).
Myocardial Tissue Properties
DHF patients had a higher CVF than did controls (7.54.0%
versus 3.82.0%, P0.05). CVF of the DHF patients who
were transplant recipients (7.53.0%) was similar to the
CVF of the other DHF patients (7.53.0%). DHF patients
were equally distributed over the 3 classes of CVF (Figure 3),
and one third of patients therefore had low interstitial fibrosis.
The higher values of LVEDP, , and E in these patients
compared with those of controls with low interstitial fibrosis
indicates that CVF is not the sole contributor to diastolic LV
dysfunction. No conspicuous differences in expression of
myosin heavy chain, desmin, actin, TnT, tropomyosin, TnI,
or MLC-1 and MLC-2 were found between DHF and control
Figure 2. A, Average force-pCa relation for pooled cardiomyo-
cytes of control and DHF groups. Ftotal at pCa 4.5 and Ca2 sen-
sitivity were similar in both groups, but Fpassive was higher in DHF
group (*P0.05). B, Average force-pCa relation for pooled car-
diomyocytes of control group before and after PKA. PKA
decreased Ca2 sensitivity and left Fpassive unaltered. (†P0.05,
after vs before PKA) C, Average force-pCa relation for pooled
cardiomyocytes of DHF group before and after PKA. PKA
decreased Ca2 sensitivity and reduced Fpassive. (†P0.05, after
vs before PKA).
Figure 3. At low (I) and intermediate (II) CVF class, DHF patients
had higher LVEDP, , and E than did controls. Numbers above
bars indicate number of individuals in each group. *P0.05,
control vs DHF within each CVF class.
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myocardium. Western immunoblot analysis did not reveal
any degradation product for desmin, TnT, TnI, MLC-1, and
MLC-2 in either group. Moreover, the MLC-1–MLC-2 ratio
did not differ between DHF patients (0.390.15) and con-
trols (0.440.11). Phosphorylation status of TnI was deter-
mined in endomyocardial biopsy samples retrieved from 7
DHF patients and 7 controls. The ratio of dephosphorylated to
total TnI was comparable in both groups (0.580.17 versus
0.530.17). Furthermore, there was no correlation between
this ratio and Fpassive.
Correlation Between In Vivo Hemodynamics and
In Vitro Force
When the DHF and control groups were combined, a mono-
variate linear regression analysis revealed significant corre-
lations between the average Fpassive of all cardiomyocytes of
each individual and the LVEDP, , or E measured in the same
individual at the time of cardiac catheterization and biopsy
sample retrieval (Figure 4). Note the quantitative agreement
between the individual values of in vivo circumferential 
and Fpassive obtained in the isolated cardiomyocytes. These
correlations were especially evident for values of Fpassive up to
5.0 kN/m2 and seemed to level off at higher values. A
monovariate linear regression analysis also revealed signifi-
cant correlations between CVF and LVEDP (R0.63,
P0.009) or  (R0.68, P0.004). In a bivariate linear
regression analysis, the combination of Fpassive and CVF
yielded stronger correlations with LVEDP (R0.80,
P0.001) or  (R0.78, P0.002) than Fpassive and CVF
alone in monovariate analysis. Fpassive and CVF were unrelated
(P0.26).
PKA and Cardiomyocyte Force Development
After PKA treatment, a second force-pCa relation could be
constructed for 11 cardiomyocytes isolated from biopsy
samples of 4 control patients and for 16 cardiomyocytes
isolated from biopsy samples of 7 DHF patients. Figure 1
(bottom) shows representative force recordings of a single
cardiomyocyte retrieved from a DHF patient before and after
PKA treatment at maximal (pCa 4.5) and intermediate (pCa
5.8) activation. At pCa 4.5, Ftotal remained the same, whereas
at pCa 5.8, Ftotal was reduced after PKA. In addition, Figure 1
illustrates the reduced Fpassive (pCa 9.0) after PKA. For control
and DHF groups, Ftotal at pCa 4.5 was similar before and after
PKA (Table 3; Figure 2B and 2C). At intermediate pCa (eg,
pCa 5.8), Ftotal was reduced after PKA because of PKA-
induced myofilament desensitization (Figure 2B and 2C). The
latter was also evident from the reduced pCa50 value observed
in both DHF and control groups (Table 3). After PKA
treatment, Fpassive of cardiomyocytes from DHF patients
dropped to values observed in the control group both at
baseline and after PKA treatment (Figures 2B, 2C, and 5A).
In addition, in DHF patients, the PKA-induced fall in Fpassive
was larger when baseline Fpassive was higher (Figure 5B).
Discussion
The present study analyzed endomyocardial biopsy samples
obtained from patients with DHF and yielded the following
information: (1) When cardiomyocytes isolated from these
samples were stretched to a sarcomere length of 2.2 m, Ftotal
at maximal [Ca2] was comparable to that of control cardio-
myocytes, but their Fpassive was twice as high. (2) The increase
in Fpassive was reversible because administration of PKA
lowered Fpassive to a level observed in control cardiomyocytes.
(3) In vivo hemodynamic measures of diastolic LV function
such as LVEDP, , and E were correlated with in vitro
measurements of both Fpassive and CVF.
High Fpassive
Because the mechanical isolation procedure removed en-
domysial collagen structures, the high Fpassive of cardiomyo-
cytes retrieved from DHF patients can only result from
deranged diastolic stiffness of the cardiomyocytes them-
selves. Because cardiomyocytes were incubated in solution
supplemented with 0.2% Triton X-100 before the experi-
ments, the integrity of sarcolemmal and sarcoplasmic mem-
branes was disrupted, and the cardiomyocytes became depen-
dent on externally supplied calcium for active force
development. Under these conditions, disturbed calcium han-
dling because of modified expression and/or phosphorylation
of sarcoplasmic reticular Ca2-ATPase,23 phospholam-
ban,24,25 sarcoplasmic calcium release channel,26 and sodium/
calcium exchanger27 is effectively ruled out as a cause of the
observed elevation of Fpassive, which therefore needs to be
attributed to alterations of myofilament or cytoskeletal
proteins.
The present study revealed no difference between the DHF
and control groups in the expression of cardiac sarcomeric
proteins such as myosin heavy chain, actin, TnT, TnI, desmin,
and tropomyosin. Protein composition may also change as a
result of enhanced proteolysis. This is especially evident for
TnI, whose calpain-mediated breakdown is accelerated by a
high LVEDP.28 Western immunoblot analysis ruled out
degradation of several contractile proteins, including TnI, in
both the control and DHF groups. Therefore, it is unlikely
that a change in isoform composition or protein degradation
accounts for the high Fpassive of cardiomyocytes observed in
the DHF group.
TABLE 3. Measures of Cardiomyocyte Force and Ca2 Sensitivity Before and After PKA Treatment
Before PKA After PKA
n Ftotal Fpassive nHill pCa50 n Ftotal Fpassive nHill pCa50
Control 15 24.212.4 3.51.7 2.240.33 5.820.08 11 24.314.1 2.61.4 2.670.47† 5.690.10†
DHF 23 20.37.5 6.63.0* 2.430.53 5.860.07 16 22.26.8 3.41.0† 2.990.59† 5.700.08†
n indicates number of cardiomyocytes.
*P0.05, DHF vs controls.
†P0.05, after vs before PKA.
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Moreover, the correction by PKA treatment provides
evidence that the high Fpassive resulted from phosphorylation of
its sarcomeric target proteins: TnI, myosin binding protein-C,
and/or titin. Treatment with PKA induced a large drop in
Fpassive in cardiomyocytes of DHF patients, whereas neither
Fpassive in control cardiomyocytes nor Ftotal at pCa 4.5 in
cardiomyocytes from both groups was altered (Table 3 and
Figure 2). Such an isolated drop in Fpassive, unaccompanied by
a fall in Ftotal, is more easily reconciled with an action of PKA
on a myofilament rather than on a cytoskeletal phosphoryla-
tion site because the parallel alignment of the cytoskeleton
with the myofilaments would predict a fall in Fpassive generated
by the cytoskeleton to also lower Ftotal.
The present study also determined the phosphorylation
status of TnI but found no difference in the ratio of
dephosphorylated to total TnI between control and DHF
groups. It has recently been demonstrated in animal studies
that phosphorylation of myosin binding protein-C and titin
modifies diastolic properties. Phosphorylation29 or expres-
sion of a mutant isoform30 releases the “braking” action of
myosin binding protein-C on cross-bridge cycling, thereby
decreasing Fpassive in skinned mouse myocardial strips.
Similarly, PKA-mediated phosphorylation of the elastic
N2B spring element of titin reduces diastolic stiffness in
isolated rat cardiomyocytes.31 Because of limited procure-
ment of myocardial tissue by endomyocardial biopsy
techniques, phosphorylation of both proteins could not be
assessed in the present study. Future studies on myocardial
tissue from DHF patients should focus on the phosphory-
lation level of both proteins to detect the sarcomeric
protein responsible for the high Fpassive of cardiomyocytes
isolated from DHF patients.
Figure 4. Correlations between Fpassive averaged for all cardio-
myocytes of each individual and LVEDP, , and E measured at
time of cardiac catheterization.
Figure 5. A, PKA treatment reduces Fpassive of DHF patients to
values observed in control group at baseline and after PKA
treatment. B, Correlation between PKA-induced fall in Fpassive
and baseline value of Fpassive.
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In Vitro Versus In Vivo
When Fpassive values of control and DHF cardiomyocytes were
pooled, in vitro measurement of Fpassive was correlated with in
vivo indices of diastolic LV dysfunction, such as LVEDP, ,
and E (Figure 4). The quantitative agreement between  and
Fpassive indicates that diastolic LV dysfunction is determined to
an important extent by the rise in Fpassive of the cardiomyo-
cytes. The relations between Fpassive and indices of diastolic
LV function all leveled off at higher values of LVEDP, , and
E. This could have resulted from diuretic therapy to recom-
pensate the patients before catheterization or from more
intense interstitial fibrosis at the top end of diastolic LV
dysfunction. In the in vitro setting, all cardiomyocytes were
stretched to the same sarcomere length of 2.2 m. In the in
vivo setting, LV preload was uncontrolled, and especially the
DHF patients, who underwent more intense diuretic therapy
in the interval between admission for pulmonary edema and
diagnostic cardiac catheterization, could have been operating
at LV filling pressures lower than needed to achieve optimal
sarcomere length. More intense interstitial fibrosis also pro-
vides an explanation for the relations between Fpassive and
indices of diastolic LV function to level off at higher values
of LVEDP, , and E. Endomyocardial biopsy samples from
patients with DHF had higher CVF than did controls, and in
a bivariate linear regression analysis, both Fpassive and CVF
were significantly correlated with LVEDP and . A predom-
inant effect of interstitial fibrosis at the top end of diastolic
LV dysfunction is in line with previous experimental studies,
which showed diastolic muscle stiffness to originate from
structures within the sarcomere for sarcomere lengths 2.2
m32 and from perimysial fibers once filling pressures
exceeded 30 mm Hg.33
Degradation of collagen in pressure-overloaded, hypertro-
phied papillary muscles with plasmin did not reduce muscle
stiffness to levels observed in normal muscles.34 Similarly, in
the present study, patients with DHF and low CVFs still had
higher LVEDP, , and E than did controls (Figure 3).
Therefore, our data support the concept that diastolic LV
dysfunction in the presence of a low CVF is explained by the
higher Fpassive of the cardiomyocytes. However, because half
of the DHF patients suffered from diabetes mellitus, collagen
cross-links formed by advanced glycation end products could
also explain the impairment of diastolic LV function at low
CVF.35
The present study observed low CVF and high Fpassive
values in some patients with DHF but failed to detect DHF
patients with high CVF and low Fpassive values. This suggests
diastolic LV dysfunction to result from a sequence of events,
which start with a rise in cardiomyocyte Fpassive followed by
the development of interstitial fibrosis. A similar sequence of
events has also been reported in experimental tachypacing-
induced HF models. In those models, elevation of diastolic
LV muscle stiffness was paralleled by expression of the
shorter and stiffer N2B isoform of titin36 and not by intersti-
tial fibrosis, which only developed when an angiotensin II
infusion was superimposed on the pacing stress.37 Similar
coordination between titin isoform shift and extracellular
matrix deposition has also been reported in other experimen-
tal models.38 The evidence provided by the present study that
DHF patients can have low CVF also explains why angio-
tensin II receptor blockers and angiotensin-converting en-
zyme inhibitors, which reduce interstitial fibrosis,39,40 have
not been uniformly successful in large clinical trials in DHF
patients.41
Study Limitations
Five of the 12 DHF patients and 6 of the 8 controls had
undergone cardiac transplantation. Transplant recipients were
included in the study because they frequently suffer DHF16
and because their myocardial biopsy material is readily
available. The pathogenetic mechanisms responsible for their
DHF could differ from that of other DHF patients because of
ongoing rejection and use of immunosuppressant drugs.
Force recordings of isolated cardiomyocytes and the extent of
interstitial fibrosis of the transplanted subgroup of DHF
patients were, however, similar to the measurements obtained
in the other DHF patients, and both data sets were therefore
merged into a single DHF group. The same also applied to the
control group.
Isolation of cardiomyocytes and assessment of myocardial
tissue properties was performed on a limited number of RV or
LV samples and could potentially have overlooked tissue
heterogeneity. The extent of tissue heterogeneity was ad-
dressed in previous studies on explanted hearts14,15 or surgi-
cally procured biopsy samples.42 In those studies, the vari-
ability of force measurements in cardiomyocytes isolated
from different portions of the heart was always 5%. To
validate the use of defrosted biopsy samples, force recordings
of cardiomyocytes isolated from a biopsy sample immedi-
ately after procurement were compared with force recordings
of cardiomyocytes isolated from a defrosted biopsy sample
from the same patient. These force recordings yielded iden-
tical results.
Conclusions
Cardiomyocytes isolated from endomyocardial biopsy sam-
ples of DHF patients had elevated Fpassive, which together with
CVF, determined in vivo diastolic LV dysfunction. Admin-
istration of PKA to these cardiomyocytes normalized Fpassive.
Because the integrity of sarcolemmal and sarcoplasmic mem-
branes was disrupted by prior Triton incubation and because
expression of sarcomeric proteins and the phosphorylation
level of TnI were unaltered, the PKA-induced fall in Fpassive
probably resulted from correction of a phosphorylation deficit
of myosin binding protein-C or titin. This hypophosphorylat-
ed sarcomeric protein could, together with extracellular
matrix modification, be a specific myocardial target for drug
therapy of DHF.
Acknowledgments
This study was supported by a Marie Curie host fellowship (contract
number HPMT-GH-00-00114-12), a European Committee Research
Training Network project (contract number HPRN-CT-2000-00091),
and the Netherlands Organization for Scientific Research (VENI
grant, 2002).
References
1. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl
J Med. 1991;325:1557–1564.
780 Circulation February 15, 2005
2. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG,
Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiolog-
ical characterization of isolated diastolic heart failure in comparison to
systolic heart failure. JAMA. 2002;288:2144–2150.
3. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and dia-
stolic heart failure, part I: diagnosis, prognosis, and measurements of
diastolic function. Circulation. 2002;105:1387–1393.
4. Redfield MM. Understanding ‘diastolic’ heart failure. N Engl J Med.
2004;350:1930–1931.
5. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F,
Freemantle N, Gavazzi A, van Gilst WH, Hobbs FD, Korewicki J,
Madeira HC, Preda I, Swedberg K, Widimsky J. Management of heart
failure in primary care (the IMPROVEMENT of Heart Failure Pro-
gramme): an international survey. Lancet. 2002;360:1631–1639.
6. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR,
Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in
the community: appreciating the scope of the heart failure epidemic.
JAMA. 2003;289:194–202.
7. Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M,
Holmer S, Doring A, Broeckel U, Riegger G, Schunkert H. Prevalence of
left ventricular diastolic dysfunction in the community: results from a
Doppler echocardiographic-based survey of a population sample. Eur
Heart J. 2003;24:320–328.
8. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—abnormalities
in active relaxation and passive stiffness of the left ventricle. N Engl
J Med. 2004;350:1953–1959.
9. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SW. Progression of
systolic abnormalities in patients with ‘isolated’ diastolic heart failure and
diastolic dysfunction. Circulation. 2002;105:1195–1201.
10. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic
and arterial stiffening in patients with heart failure and preserved ejection
fraction: implications for systolic and diastolic reserve limitations. Cir-
culation. 2003;107:714–720.
11. Pak PH, Maughan L, Baughman KL, Kass DA. Marked discordance
between dynamic and passive diastolic pressure-volume relations in idio-
pathic hypertrophic cardiomyopathy. Circulation. 1996;94:52–60.
12. Morris-Thurgood JA, Frenneaux MP. Diastolic ventricular interaction
and ventricular diastolic filling. Heart Fail Rev. 2000;5:307–323.
13. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic
dysfunction in heart failure? Circ Res. 2004;94:1533–1542.
14. van der Velden J, Klein LJ, Zaremba R, Boontje NM, Huybregts MA,
Stooker W, Eijsman L, de Jong JW, Visser CA, Visser FC, Stienen GJM.
Effects of calcium, inorganic phosphate, and pH on isometric force in
single skinned cardiomyocytes from donor and failing human hearts.
Circulation. 2001;104:1140–1146.
15. van der Velden J, Papp Z, Zaremba R, Boontje NM, de Jong JW, Owen
VJ, Burton PB, Goldmann P, Jaquet K, Stienen GJM. Increased Ca2-
sensitivity of the contractile apparatus in end-stage human heart failure
results from altered phosphorylation of contractile proteins. Cardiovasc
Res. 2003;57:37–47.
16. How to diagnose diastolic heart failure. European Study Group on dia-
stolic heart failure. Eur Heart J. 1998;19:990–1003.
17. Papp Z, Szabo A, Barends JP, Stienen GJM. The mechanism of the force
enhancement by MgADP under simulated ischaemic conditions in rat
cardiac myocytes. J Physiol. 2002;543:177–189.
18. Bronzwaer JG, Heymes C, Visser CA, Paulus WJ. Myocardial fibrosis
blunts nitric oxide synthase–related preload reserve in human dilated
cardiomyopathy. Am J Physiol. 2003;284:H10–H16.
19. van der Velden J, Moorman AF, Stienen GJM. Age-dependent changes in
myosin composition correlate with enhanced economy of contraction in
guinea-pig hearts. J Physiol. 1998;507:497–510.
20. Paulus WJ, Heyndrickx GR, Buyl P, Goethals MA, Andries E.
Wide-range load shift of combined aortic valvuloplasty-arterial vasodi-
lation slows isovolumic relaxation of the hypertrophied left ventricle.
Circulation. 1990;81:886–898.
21. Bronzwaer JG, de Bruyne B, Ascoop CA, Paulus WJ. Comparative
effects of pacing-induced and balloon coronary occlusion ischemia on left
ventricular diastolic function in man. Circulation. 1991;84:211–222.
22. Bronzwaer JG, Zeitz C, Visser CA, Paulus WJ. Endomyocardial nitric
oxide synthase and the hemodynamic phenotypes of human dilated car-
diomyopathy and of athlete’s heart. Cardiovasc Res. 2002;55:270–278.
23. Frank KF, Bolck B, Brixius K, Kranias EG, Schwinger RH. Modulation
of SERCA: implications for the failing human heart. Basic Res Cardiol.
2002;97(suppl 1):I-72–I-78.
24. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of
cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566–577.
25. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol
Cell Cardiol. 2002;34:951–969.
26. Marks AR, Reiken S, Marx SO. Progression of heart failure: is protein
kinase A hyperphosphorylation of the ryanodine receptor a contributing
factor? Circulation. 2002;105:272–275.
27. Weber CR, Piacentino V III, Houser SR, Bers DM. Dynamic regulation
of sodium/calcium exchange function in human heart failure. Circulation.
2003;108:2224–2229.
28. Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty JM Jr. Preload induces
troponin I degradation independently of myocardial ischemia. Circu-
lation. 2001;103:2035–2037.
29. Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac
myosin binding protein C: its role in physiology and disease. Circ Res.
2004;94:1279–1289.
30. Palmer BM, Georgakopoulos D, Janssen PM, Wang Y, Alpert NR,
Belardi DF, Harris SP, Moss RL, Burgon PG, Seidman CE, Seidman JG,
Maughan DW, Kass DA. Role of cardiac myosin binding protein C in
sustaining left ventricular systolic stiffening. Circ Res. 2004;94:
1249–1255.
31. Yamasaki R, Wu Y, McNabb M, Greaser M, Labeit S, Granzier H.
Protein kinase A phosphorylates titin’s cardiac-specific N2B domain and
reduces passive tension in rat cardiac myocytes. Circ Res. 2002;90:
1181–1188.
32. Linke WA, Popov VI, Pollack GH. Passive and active tension in single
cardiac myofibrils. Biophys J. 1994;67:782–792.
33. Factor SM, Flomenbaum M, Zhao MJ, Eng C, Robinson TF. The effects
of acutely increased ventricular cavity pressure on intrinsic myocardial
connective tissue. J Am Coll Cardiol. 1988;12:1582–1589.
34. Stroud JD, Baicu CF, Barnes MA, Spinale FG, Zile MR. Viscoelastic
properties of pressure overload hypertrophied myocardium: effect of
serine protease treatment. Am J Physiol. 2002;282:H2324–H2335.
35. Herrmann KL, McCulloch AD, Omens JH. Glycated collagen cross-
linking alters cardiac mechanics in volume-overload hypertrophy. Am J
Physiol. 2003;284:H1277–H1284.
36. Wu Y, Bell SP, Trombitas K, Witt CC, Labeit S, LeWinter MM, Granzier
H. Changes in titin isoform expression in pacing-induced cardiac failure
give rise to increased passive muscle stiffness. Circulation. 2002;106(:
1384–1389.
37. Senzaki H, Paolocci N, Gluzband YA, Lindsey ML, Janicki JS, Crow
MT, Kass DA. -Blockade prevents sustained metalloproteinase acti-
vation and diastolic stiffening induced by angiotensin II combined with
evolving cardiac dysfunction. Circ Res. 2000;86:807–815.
38. Wu Y, Cazorla O, Labeit D, Labeit S, Granzier H. Changes in titin and
collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol
Cell Cardiol. 2000;32:2151–2162.
39. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myo-
cardial fibrosis in patients with hypertensive heart disease. Circulation.
2000;102:1388–1393.
40. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J,
Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M.
Myocardial stiffness is determined by ventricular fibrosis, but not by
compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc
Res. 2002;55:76–82.
41. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ,
Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients
with chronic heart failure and preserved left-ventricular ejection fraction:
the CHARM-Preserved Trial. Lancet. 2003;362:777–781.
42. van der Velden J, Klein LJ, van der Bijl M, Huybregts MA, Stooker W,
Witkop J, Eijsman L, Visser CA, Visser FC, Stienen GJ. Isometric tension
development and its calcium sensitivity in skinned myocyte-sized prep-
arations from different regions of the human heart. Cardiovasc Res.
1999;42:706–719.
Borbély et al Cardiomyocyte Stiffness in Diastolic HF 781
